Feed Preview

Breast Cancer Triple-N

Breast Cancer Triple-N diagram by National Cancer Institute (Public Domain)
National Cancer Institute (Public Domain)

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Top 20 most recent papers
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

Journal of Clinical Oncology : Official Journal of the American Society of Clinical OncologyDecember 5, 2019
Ana M Lluchand LACOG (Latin American Cooperative Oncology Group)
20
The Lancet Oncology

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet OncologyNovember 27, 2019
Peter SchmidIMpassion130 Investigators
57
1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis

Clinical Cancer Research : an Official Journal of the American Association for Cancer ResearchDecember 3, 2019
Melinda L TelliAndrea Lynn Richardson
bioRxiv

Single-cell RNA-seq data reveals TNBC tumor heterogeneity through characterizing subclone compositions and proportions

bioRxivNovember 28, 2019
Wei-Da WangYun Xiao
16
bioRxiv

Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor

bioRxivNovember 29, 2019
Tiffany ChangBridgette M. Collins-Burow
4
bioRxiv

The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype

bioRxivNovember 29, 2019
Alejandro Javier EspañolMaría Elena Sales
bioRxiv

Sporadic activation of an oxidative stress-dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies

bioRxivDecember 5, 2019
Elizabeth J. PereiraKevin A. Janes
14
Indian Journal of Cancer

Mainstreaming genetic counseling for BRCA testing into oncology clinics - Indian perspective

Indian Journal of CancerNovember 1, 2019
Amit VermaVeda Padama Priya Selvakumar
1
International Journal of Molecular Sciences

Clinical Implications of Extracellular HMGA1 in Breast Cancer

International Journal of Molecular SciencesNovember 26, 2019
Olga MéndezJosep Villanueva
International Journal of Molecular Sciences

Preclinical Evaluation of Ureidosulfamate Carbonic Anhydrase IX/XII Inhibitors in the Treatment of Cancers

International Journal of Molecular SciencesDecember 2, 2019
Kaye Janine Williams, Roben G Gieling
International Journal of Molecular Sciences

CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges

International Journal of Molecular SciencesNovember 26, 2019
Dennis C HarrerNiels Schaft
1
British Journal of Cancer

Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples

British Journal of CancerDecember 3, 2019
Alexandre Ho-Pun-CheungEvelyne Lopez-Crapez
Advanced Healthcare Materials

Acid-Triggered Charge-Convertible Graphene-Based All-in-One Nanocomplex for Enhanced Genetic Phototherapy of Triple-Negative Breast Cancer

Advanced Healthcare MaterialsDecember 4, 2019
Chun-Hui WuYiyao Liu
Oncology Letters

Long non-coding RNA heart and neural crest derivatives expressed 2-antisense RNA 1 overexpression inhibits the proliferation of cancer cells by reducing RUNX2 expression in triple-negative breast cancer

Oncology LettersDecember 1, 2019
Min WeiZhi-wei Wang
Journal of Translational Medicine

The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice

Journal of Translational MedicineNovember 28, 2019
Marina DegoricijaJanos Terzić
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

Enhancing the abscopal effect of radiation and immune checkpoint inhibitor therapies with magnetic nanoparticle hyperthermia in a model of metastatic breast cancer

International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia GroupNovember 1, 2019
Arlene L OeiRobert Ivkov
Oncology Letters

Prognostic phenotypic classification for canine mammary tumors

Oncology LettersDecember 1, 2019
Giovanna Rossi VaralloDébora Aparecida Pires de Campos Zuccari
Aging

EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC

AgingDecember 4, 2019
Y Lucy LiuJing-Zhong Zhang
1
Oncology Letters

MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition

Oncology LettersDecember 1, 2019
Xiao-qing GuanJi Wu
1
The Lancet Oncology

Building momentum for subsets of patients with advanced triple-negative breast cancer

The Lancet OncologyNovember 27, 2019
Wendy Ann Woodward

See more papers from this feed

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Cancer: Risk Factors

Breast cancer is a multifactorial disease that is influenced by both environmental and genetic factors. Discover the latest research on the environmental and genetic risk factors for breast cancer here.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Carcinoma, Lobular

Lobular carcinoma is an invasive type of breast cancer in which lobules, areas of the breast that produce milk, undergo malignant transformation. Here is the latest research.

Hereditary Breast & Ovarian Cancer

Hereditary breast and ovarian cancer due to mutations in the brca1 and brca2 genes is the most common cause of hereditary forms of both breast and ovarian cancer. Here are the latest discoveries pertaining to these cancers.

Inflammatory Breast Neoplasms

Inflammatory breast cancer is a rare disease characterized by edema and redness of the breast. This is caused by metastatic breast cancer cells blocking lymphatic vessels. Discover the latest research on Inflammatory breast cancer here.

© 2019 Meta ULC. All rights reserved
/feed-previews/breast-cancer-triple-n/45339d98-9700-4a1e-b71b-7e3d216b29ac